Amycretin
Amycretin is a single molecule serving as a GLP-1 receptor agonist and an amylin receptor agonist. It is made by the Danish pharmaceutical company Novo Nordisk as a weight loss drug to be taken by mouth.[1] A form that can be injected via human skin is also under study.[1]
Mechanism of action
The drug has a dual mechanism of action affecting appetite regulation and metabolism,[2] which makes it different from other drugs being made for weight loss.[2]
Research
The company announced the results from the Phase I trial of amycretin's pill form.[3] The company further announced the results of its 1B/2A trial in January 2025.[4] The trial investigated the drug's safety, tolerability, and pharmacokinetics by injecting it into 125 patients via their skin.[4] The treatment lasted up to 36 weeks.[4]
References
- ↑ 1.0 1.1
- Lua error in Module:Citation/CS1/Identifiers at line 630: attempt to index field 'known_free_doi_registrants_t' (a nil value).
- Melson, Eka; Ashraf, Uzma; Papamargaritis, Dimitris; Davies, Melanie J. (February 1, 2024). "What is the pipeline for future medications for obesity?". International Journal of Obesity: 1–19. doi:10.1038/s41366-024-01473-y. ISSN 1476-5497.
- Lua error in Module:Citation/CS1/Identifiers at line 630: attempt to index field 'known_free_doi_registrants_t' (a nil value).
- Linnane, Ciara. "Viking Therapeutics faces higher bar for oral weight-loss drug" (in EN-US). MarketWatch. https://www.marketwatch.com/story/viking-therapeutics-faces-higher-bar-for-oral-weight-loss-drug-after-strong-readout-from-rival-72c531c4. Retrieved March 11, 2024.
- Lua error in Module:Citation/CS1/Identifiers at line 630: attempt to index field 'known_free_doi_registrants_t' (a nil value).
- ↑ 2.0 2.1 Gasiorek A, Heydorn A, Kirkeby K, Key C, Toubro S, Schefe LH, Dahl K, Hjerpsted JB, Vegge A (September 2024). "Safety, tolerability and weight reduction findings of oral amycretin: a novel amylin and glucagon-like peptide-1 receptor co-agonist, in a first-in-human study". Diabetologia. Springer. 67: S42–S43.
- ↑ ""Novo valuation surpasses Tesla on experimental obesity drug data"". Reuters. March 7, 2024. Retrieved 2024-03-13.
- ↑ 4.0 4.1 4.2 "Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity". Novo Nordisk. January 24, 2025. Retrieved 2025-01-29.
